keyword
MENU ▼
Read by QxMD icon Read
search

Dactinomycin aml

keyword
https://www.readbyqxmd.com/read/24904937/after-the-treated-mole
#1
Armin Rashidi, Elaine M Maherus
No abstract text is available yet for this article.
May 1, 2014: Blood
https://www.readbyqxmd.com/read/24857206/-prospective-multicentre-study-of-chemotherapeutic-regimen-containing-pirarubicin-on-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-in-adults
#2
RANDOMIZED CONTROLLED TRIAL
Feng Chen, Jingxia Wang, Ming Hou, Hongguo Zhao, Enqin Yang, Xuehong Ran, Minglin Wang, Wenzheng Yu, Ruirong Xu, Zhencheng Wang, Kehong Bi, Xin Wang, Guoqiang Liu, Sheng Yang, Jin Fan, Lingling Wang
OBJECTIVE: To compare the efficacy and toxicity of the chemotherapeutic regimen containing pirarubicin and mitoxantrone on the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults. METHODS: In this open prospective multicentre study, we randomly assigned patients with relapsed or refractory AML to receive TAE regimen (pirarubicin+cytarabine+etoposide) versus MAE regimen (mitoxantrone + cytarabine + etoposide). The efficacy and toxicity were compared between the two groups...
May 2014: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/21949608/systematic-in-vitro-evaluation-of-the-nci-nih-developmental-therapeutics-program-approved-oncology-drug-set-for-the-identification-of-a-candidate-drug-repertoire-for-mll-rearranged-leukemia
#3
Kimberley A Hoeksema, Aarthi Jayanthan, Todd Cooper, Lia Gore, Tanya Trippett, Jessica Boklan, Robert J Arceci, Aru Narendran
Despite significant progress made in the overall cure rate, the prognosis for relapsed and refractory malignancies in children remains extremely poor. Hence, there is an urgent need for studies that enable the timely selection of appropriate agents for Phase I clinical studies. The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) is systematically evaluating libraries of known and novel compounds for activity against subsets of high-risk pediatric malignancies with defined molecular aberrations for future clinical development...
2011: OncoTargets and Therapy
https://www.readbyqxmd.com/read/19067904/secondary-leukemia-in-a-child-conceived-using-in-vitro-fertilization
#4
Young Dae Kim, Ki Joong Kim, Young Ho Lee
No abstract text is available yet for this article.
December 2008: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/16985182/therapy-related-myelodysplasia-and-acute-myeloid-leukemia-after-ewing-sarcoma-and-primitive-neuroectodermal-tumor-of-bone-a-report-from-the-children-s-oncology-group
#5
RANDOMIZED CONTROLLED TRIAL
Smita Bhatia, Mark D Krailo, Zhengjia Chen, Laura Burden, Frederic B Askin, Paul S Dickman, Holcombe E Grier, Michael P Link, Paul A Meyers, Elizabeth J Perlman, Aaron R Rausen, Leslie L Robison, Teresa J Vietti, James S Miser
This study describes the magnitude of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children's Oncology Group therapeutic protocol, INT-0091. Between 1988 and 1992, patients with or without metastatic disease were randomized to receive doxorubicin, vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs alternating with etoposide and ifosfamide (regimen B). Between 1992 and 1994, patients with metastatic disease were nonrandomly assigned to receive high-intensity therapy (regimen C: regimen B therapy with higher doses of doxorubicin, cyclophosphamide, and ifosfamide)...
January 1, 2007: Blood
https://www.readbyqxmd.com/read/15895438/quantification-of-t-cell-mediated-apoptosis-in-heterogeneous-leukemia-populations-using-four-color-multiparameter-flow-cytometry
#6
Theresia M Westers, Ilse Houtenbos, Gerrit Jan Schuurhuis, Gert J Ossenkoppele, Arjan A van de Loosdrecht
BACKGROUND: The unique capacity of dendritic cells to present antigens to naive T cells is being increasingly utilized in cancer therapy. The efficacy of cell-based immunotherapy can be analyzed by determination of cytotoxic activity of T cells toward tumor cells in vitro. This study supplies a flow cytometric method to analyze T-cell-mediated cytotoxic activity toward heterogeneous leukemic cell populations at a single-cell level. METHODS: The fluorescent probe SYTO16 and the dead-cell dye 7-aminoactinomycine-D (7-AAD) were used to identify early and late stages of apoptosis in combination with leukemia cell-identifying markers...
July 2005: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/15788130/induction-of-apoptosis-by-homoharringtonine-in-g1-phase-human-chronic-myeloid-leukemic-cells
#7
Wen-yuan Mai, Mao-fang Lin
BACKGROUND: Homoharringtonine (HHT) is a cephalotaxine ester derived from an evergreen tree found wildely throughout southern China, which has antileukemic activities against a variety of acute myeloid leukemic cells. For the sake of illustrating the mechanisms of HHT in the treatment of leukemia, we assessed the effect of HHT on the apoptosis of human chronic myeloid leukemic cell line K562. METHODS: The apoptosis of K562 cells induced by HHT was analyzed by transmission electron microscopy, agarose gel electrophoresis of DNA, flow cytometry and terminal deoxyribonucleotidyl transferase-mediated dUTP-biotin nick labeling...
March 20, 2005: Chinese Medical Journal
https://www.readbyqxmd.com/read/12365021/second-malignant-neoplasms-in-long-term-survivors-of-osteosarcoma-memorial-sloan-kettering-cancer-center-experience
#8
LeLe Aung, Richard G Gorlick, Weiji Shi, Howard Thaler, Nicholas A Shorter, John H Healey, Andrew G Huvos, Paul A Meyers
BACKGROUND: The authors investigated the incidence and relative risk of secondary malignant neoplasms in long-term survivors of osteosarcoma. METHODS: A comprehensive list of 509 patients with primary osteosarcoma treated at our institution between February 1973 and March 2000 was identified. All study patients received chemotherapy and/or surgery on one of six different protocols (T4, 5, 7, 10, 12, and CCG-7921/POG-9351). Chemotherapy was scheduled for up to 40 weeks with some variations in the actual treatment period and consisted of various combinations of the following agents: high-dose methotrexate, doxorubicin, bleomycin, cyclophosphamide, dactinomycin, vincristine, cisplatin, and ifosfamide...
October 15, 2002: Cancer
https://www.readbyqxmd.com/read/11493704/near-precise-interchromosomal-recombination-and-functional-dna-topoisomerase-ii-cleavage-sites-at-mll-and-af-4-genomic-breakpoints-in-treatment-related-acute-lymphoblastic-leukemia-with-t-4-11-translocation
#9
B D Lovett, L Lo Nigro, E F Rappaport, I A Blair, N Osheroff, N Zheng, M D Megonigal, W R Williams, P C Nowell, C A Felix
We analyzed the der(11) and der(4) genomic breakpoint junctions of a t(4;11) in the leukemia of a patient previously administered etoposide and dactinomycin by molecular and biochemical approaches to gain insights about the translocation mechanism and the relevant drug exposure. The genomic breakpoint junctions were amplified by PCR. Cleavage of DNA substrates containing the normal homologues of the MLL and AF-4 translocation breakpoints was examined in vitro upon incubation with human DNA topoisomerase IIalpha and etoposide, etoposide catechol, etoposide quinone, or dactinomycin...
August 14, 2001: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/10797445/three-color-versus-four-color-multiparameter-cell-cycle-analyses-of-primary-acute-myeloid-leukemia-samples
#10
S M Garrido, C Willman, F R Appelbaum, D E Banker
Checkpoint alterations that impact cell cycle and apoptosis responses to therapeutic treatments may produce drug resistance in acute myeloid leukemia (AML). To study these, we have developed flow cytometry assays of checkpoint function that also allow quantitation of key molecular regulators of apoptosis and cell cycle. We have used three-color (3C) assays, with FITC-labeled anti-BCL-2 and PE-labeled anti-proliferating cell nuclear antigen (PCNA) antibodies, and the DNA dye 7-aminoactinomycin, to characterize primary leukemia cells identified in DNA x side light scatter (SSC) histograms...
April 15, 2000: Cytometry
https://www.readbyqxmd.com/read/10779437/p-glycoprotein-plays-a-drug-efflux-independent-role-in-augmenting-cell-survival-in-acute-myeloblastic-leukemia-and-is-associated-with-modulation-of-a-sphingomyelin-ceramide-apoptotic-pathway
#11
M Pallis, N Russell
P-glycoprotein (pgp), which is the product of the MDR1 (multidrug resistance-1) gene, has an established role as a mediator of cytotoxic drug resistance in acute myeloid leukemia (AML). To study the role of pgp in mediating apoptosis resistance in AML cells deprived of serum and growth factors, apoptosis was quantified by flow cytometry using uptake of the dye 7-amino-actinomycin D (7-AAD) alongside low forward scatter. In pgp+ve primary AML samples, there was a significant increase in apoptosis in the presence of the pgp-specific antibody UIC2 (mean increase: 58%; range: 11%-95%; P <...
May 1, 2000: Blood
https://www.readbyqxmd.com/read/10764145/sensitisation-of-hl60-human-leukaemic-cells-to-cytotoxic-drug-induced-apoptosis-by-inhibition-of-pi3-kinase-survival-signals
#12
D M O'Gorman, S L McKenna, A J McGahon, K A Knox, T G Cotter
Drug resistance remains a serious limiting factor in the treatment of acute myeloid leukaemia (AML) either at initial presentation or following primary or subsequent relapses. Using specific kinase inhibitors, this study has investigated the contribution of the Ras/PI3-kinase regulated survival pathways to drug resistance and suppression of apoptosis in a cell line derived from AML (HL60). Inhibition of the Raf/MAP-kinase (ERK) pathway with a specific MAP-kinase inhibitor, apigenin did not sensitise HL60 cells to drug-induced apoptosis, indicating a lack of involvement in chemoresistance...
April 2000: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/10680701/cell-kinetic-study-of-normal-human-bone-marrow-hematopoiesis-and-acute-leukemia-using-7aad-py
#13
K Toba, T Koike, K Watanabe, I Fuse, M Takahashi, S Hashimoto, H Takahashi, T Abe, T Yano, Y Shibazaki, H Itoh, Y Aizawa
We have used the 7AAD/PY method to analyze the cell cycle status of normal human bone marrow hematopoiesis, and found that the cell kinetics differed. There were cells with relatively low levels of RNA in the S-phase (Type I) and a high level in the S-phase (Type 11). T-cells, B-cells, nucleated red cells and CD34+/CD19+ early B-cells in bone marrow were Type I, whereas myelomonocytic subset and CD34+/CD33-dim+ common myeloid cells were Type II. AC133+/CD38-dim cells, which were thought to be lineage-marker negative hematopoietic stem cells, had intermediate amounts of RNA in the S-phase between Type I and II (Type 0)...
January 2000: European Journal of Haematology
https://www.readbyqxmd.com/read/10547616/flow-cytometric-chemosensitivity-analysis-of-blasts-from-patients-with-acute-myeloblastic-leukemia-and-myelodysplastic-syndromes-the-use-of-7aad-with-antibodies-to-cd45-or-cd34
#14
M Pallis, J Syan, N H Russell
BACKGROUND: Flow cytometry is potentially suited to the chemosensitivity analysis of peripheral blood or bone marrow subpopulations in patients with leukaemia and myelodysplastic syndromes. METHODS: The use of the fluorescent dye 7-amino-actinomycin (7AAD) on unfixed cells to measure loss of viability at a range of cytosine arabinoside (ara-C) doses was evaluated. A six-tube flow cytometric assay for measuring the sensitivity to ara-C of CD45/side-scatter-gated or of CD34-positive leukemic blasts with 7AAD was established, using fixed stained normal mononuclear cells as an internal standard for quantitation of viable cells following culture...
December 1, 1999: Cytometry
https://www.readbyqxmd.com/read/9788419/second-malignancies-after-treatment-for-ewing-s-sarcoma-a-report-of-the-cess-studies
#15
MULTICENTER STUDY
J Dunst, S Ahrens, M Paulussen, C Rübe, W Winkelmann, A Zoubek, D Harms, H Jürgens
PURPOSE: During recent years, more intensified systemic and local treatment regimens have increased the 5-year survival figures in localized Ewing's sarcoma to more than 60%. There is, however, concern about the risk of second malignancies (SM) in long-term survivors. We have analyzed the second malignancies in patients treated in the German Ewing's Sarcoma Studies CESS 81 and CESS 86. MATERIALS AND METHODS: From January 1981 through June 1991, 674 patients were registered in the two sequential multicentric Ewing's sarcoma trials CESS 81 (recruitment period 1981-1985) and CESS 86 (1986-1991)...
September 1, 1998: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/9513872/management-of-resistant-gestational-trophoblastic-tumors
#16
E S Newlands, M Bower, L Holden, D Short, M J Seckl, G J Rustin, R H Begent, K D Bagshawe
OBJECTIVE: To analyze the causes of therapeutic success and failure in the management of patients with high-risk gestational trophoblastic tumors (GTTs). STUDY DESIGN: Analysis of 272 consecutive high-risk patients treated at the trophoblastic disease center at the Charing Cross Hospital between 1979 and 1995. RESULTS: EMA (etoposide, methotrexate, actinomycin D)/CO (cyclophosphamide, vincristine) chemotherapy is our treatment of choice for patients with high-risk GTT...
February 1998: Journal of Reproductive Medicine
https://www.readbyqxmd.com/read/9215835/ema-co-for-high-risk-gestational-trophoblastic-tumors-results-from-a-cohort-of-272-patients
#17
M Bower, E S Newlands, L Holden, D Short, C Brock, G J Rustin, R H Begent, K D Bagshawe
PURPOSE: To evaluate the results of etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) chemotherapy in women with high-risk gestational trophoblastic tumors (GTT) and to document the middle- and long-term toxicity of the regimen. PATIENTS AND METHODS: A total of 272 consecutive women with high-risk GTT, including 121 previously treated patients, were treated with weekly EMA/CO. The median follow-up duration is 4...
July 1997: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/9180915/therapy-related-acute-myeloid-leukemia-with-t-8-21-in-a-child-with-previous-ewing-s-sarcoma
#18
J F Lesesve, P Schneider, I Dolgopolov, C Bastard, B Lenormand, E Cambon-Michot, M P Callat, B Cavelier, P H Tron, J P Vannier
Cases of secondary acute myeloid leukemia (AML) occurring after treatment for an Ewing's sarcoma are uncommon. Therapy-related AML with t(8;21) translocation is an entity which has been well characterized. A case of AML-2 with t(8;21) and t(3;15) occurring 4 years after treatment for an Ewing's sarcoma with cyclophosphamide, doxorubicin, vincristine, dactinomycin, and radiotherapy, is reported. Autologous bone marrow transplantation was performed during second remission, 23 months after diagnosis. Reverse transcriptase polymerase chain reaction of the AML1/ETO fusion gene product was performed in order to monitor the quality of the remission...
August 1997: Medical and Pediatric Oncology
https://www.readbyqxmd.com/read/9180294/regulation-of-bcl-6-gene-expression-in-human-myeloid-monocytoid-leukemic-cells
#19
T Yamochi, A Kitabayashi, M Hirokawa, A B Miura, T Onizuka, S Mori, M Moriyama
We demonstrated in the present study that the BCL-6 transcripts were detectable not only in B cells, but also in circulating granulocytes and monocytes from normal individuals, and in human acute nonlymphocytic leukemia cells of certain subtypes (M3, M4, M5). Then, with an assumption that the BCL-6 gene expression may be related to the differentiation of myeloid cells, we analyzed the inducibility of BCL-6 gene expression along monocytic lineage differentiation in HL-60 and U-937 cells by treating them with 12-O-tetradecanoylphorbol-13-acetate (TPA)...
May 1997: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/9096688/topoisomerase-ii-inhibitors-induce-dna-double-strand-breaks-at-a-specific-site-within-the-aml1-locus
#20
M Stanulla, J Wang, D S Chervinsky, P D Aplan
Treatment-related acute myeloid leukemia (t-AML) following successful therapy of a primary malignancy has been recognized with increasing frequency among cancer survivors over the past several years. Many of these t-AML cases are associated with the use of intensive chemotherapy regimens that employ one or more agents which target eukaryotic topoisomerase II (topo II), and demonstrate non-random chromosomal translocations involving either the MLL (ALL-1, HRX) gene at 11q23 or the AML1 gene at 21q22. Although many investigators have speculated that these translocations are induced by the therapeutic use of topo II inhibitors, the molecular sequence of events by which topo II inhibitors might induce a chromosomal translocation are not well understood...
April 1997: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
79190
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"